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ABSTRACT
Objectives: Surgical site infection (SSI) following gynecologic oncology surgery is a severe problem for both patient 
and surgeon in terms of increasing morbidity, length of hospital stay, anxiety, and costs. In this prospective, randomized, 
controlled study we investigated the effect of subcutaneous rifampicin and povidone-iodine on incisional SSI following 
gynecologic oncology surgery. 
Material and methods: Three hundred patients scheduled for abdominal surgery due to any malign gynecological pa-
thology were randomly assigned into one of three groups of 100 members each, as follows: the subcutaneous tissue was 
irrigated with saline in Group 1; saline + 10% povidone iodine in Group 2; saline + rifampicin in Group 3. Patients were 
invited to follow-up once every 10 days in a 30-day period for evaluation. Patients who developed a superficial incisional 
SSI were recorded. 
Results: No significant relationship was observed between the SSI and the subcutaneous agents used (p = 0.332). It was 
observed that there was a statistically significant increase in the rate of incisional surgical site infections as the period 
of hospitalization (p = 0.044), patient’s age (p = 0.003), existence of comorbidities (p = 0.001), and perioperative blood 
transfusion (p = 0.021) increased.
Conclusions: Subcutaneous agents are not effective in preventing surgical site infections after gynecologic oncology 
surgeries. Further large-scale prospective randomized controlled studies may provide other options to prevent SSIs.
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INTRODUCTION
The incidence of surgical site infections (SSIs) is 5–16%, 
and they are observed in 6–15% of gynecologic oncology 
cases [1, 2]. The infections in this patient group are much 
more important and riskier than the others because it may 
increase the patient’s morbidity, cause delay in adjuvant 
therapy and additional treatment due to infection, thereby 
increasing the cost of care [3].
Chronic diseases, advanced age, smoking, hypoal-
buminemia, malnutrition, hypothermia, hyperglycemia, 
prolonged hospital stay, perioperative blood transfusion, 
and corticosteroids and other immunosuppressive agents 
can increase superficial incisional SSI rates by adversely 
affecting the host defense. At the same time, the architec-
tural characteristics and ventilation of the operating room, 
surgical clothing, surgical hand washing, preparation of 
the incision site under appropriate conditions, prophylactic 
antibiotic use, surgical technique, the materials used dur-
ing surgery, and length of surgery also affect superficial 
incisional SSI rates [4, 5].
Despite the developments in the sterilization methods, 
operation room conditions, and intensive care unit facilities, 
SSI continues to constitute a serious problem for surgery. In 
order to establish a diagnosis according to certain criteria and 
access more accurate statistical data in infections that occur 
after surgery, Centers for Disease Control and Prevention of the 
United States of America provided standard definitions, and it 
was accepted to use the definition “Surgical Site Infection” [6]. 
According to the standard definitions provided by this center, 
the SSIs were grouped into two: incisional and organ/site in-
fection. The incisional SSI is observed within 30 days after the 
operation and constitutes 2/3 of the surgical site infections [7].
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An increase has recently been observed in the incidence 
of SSI particularly in gynecologic oncology cases due to 
reasons such as that elderly individuals with chronic diseases 
are more commonly operated compared to the past and 
long and complicated operations are performed [8].
The factors that play a role in the occurrence of surgical 
site infections can be listed as bacteria load and virulence, 
tissue factor, and other factors associated with the patient. 
The source of the pathogens are usually the endogenous 
flora caused by the patient’s skin, mucous membranes, or 
intestinal system. The microorganisms contained in the pa-
tient’s skin and mucosa are the most significant reservoir of 
the incisional surgical site infections in particular; therefore, 
antibiotics prophylaxis, providing preoperative local cleaning, 
eliminating the debris when the skin incision is closed and 
washing the wound abundantly, and providing appropriate 
local antisepsis decreases the risk of incisional wound infec-
tion [9]. The World Health Organization recommended 16-
item measures for SSI prevention in 2016 [10]. In this package 
of measures, incisional wound irrigation with antibiotics and 
povidone-iodine has been recommended along with impor-
tant preventions like perioperative oxygenation, maintaining 
normal body temperature, intensive blood glucose control, 
adequate circulating volume control. The data on the topical 
antibiotic use to prevent surgical site infections is limited. Ri-
fampicin is a cheap and easily accessible semi-synthetic, high 
topical effect antibiotic which is very strong bactericidal on 
many Gram (+) and (−) bacteria including S. aureus [11–13]. 
For these reasons, we have been using rifampicin as a topical 
antibiotic for many years in our practice.
Objectives
We have previously evaluated the effects of subcutane-
ous agents used in benign gynecologic cases on SSI forma-
tion [14]. Also, there is a limited number of studies in the 
literature about the SSIs observed after gynecologic oncol-
ogy cases in particular. Therefore, we compared the efficacy 
of the subcutaneous rifampicin and 10% povidone-iodine 
used for preventing the incisional SSI in gynecologic on-
cology cases in this preliminary prospective randomized 
controlled study which is the second leg of SSI research in 
obstetrics& gynecology. Furthermore, the other factors that 
could cause SSI were evaluated.
MATERIAL AND METHODS
The Ethical Committee of Gaziantep University approved 
the study protocol (2018/156), and written informed con-
sent was obtained from all patients before enrollment.
Three hundred patients who had no pregnancy and ac-
tive infection and who were decided to have abdominal 
surgery due to gynecologic malignancy between February 
2018 and July 2019 in the Gynecology and Obstetrics Clinic of 
Gaziantep University Faculty of Medicine were grouped into 
3 groups of 100 people in a randomized manner. Each patient 
that was operated on  between the dates mentioned above 
was included in the groups in turn. It was randomly specified 
which subcutaneous agent would be used for which patient. 
After the abdominal operation was completed and the ab-
dominal fascia was closed, the subcutaneous tissue was irri-
gated only with saline in Group 1 (control group), saline + 10% 
povidone-iodine in Group 2, and saline + rifampicin in Group 
3. All subcutaneous tissues were irrigated with 250 mL of 
saline. Then 10 mL of 10 % povidone-iodine in Group 2 and 
500 mg/6 mL of rifampicin in Group 3 was applied directly on 
the subcutaneous tissue without being diluted. The excess 
liquid was cleaned off and the subcutaneous tissue scrubbed 
with a gauze. A five-point gynecological perioperative in-
fection prevention bundle was used in all groups [15]. This 
bundle includes 5 preoperative measures as; chlorhexidine 
wash using 4% chlorhexidine gluconate wipes, mechani-
cal bowel preparation with oral antibiotics preoperatively, 
antibiotic and skin preparation administration, adoption of 
enhanced sterile techniques during intestinal resection and 
wound closure perioperatively, and strict wound manage-
ment postoperatively. All groups were operated in the same 
operating room under the same technical conditions with the 
same team. The subcutaneous thickness was grouped into 
3 according to the measurements; thin ≤ 4 cm, moderate: 
5–9 cm, thick ≥ 10 cm. The 10-Fr hemovac drains (400 cc) were 
inserted subcutaneously and 2/0 polyglactin 910 (Vicryl®) 
was used as a subcutaneous suture in moderate and thick 
groups. Subcuticular 3–0 modified glycolic acid (Monosyn®) 
was used for the skin in pfannenstiel incisions, and subcuticu-
lar 3–0 polypropylene (PP, Premilene®) or staple was used for 
the skin in midline incisions. The patients were discharged 
with Cefazolin 1 gram/day and Naproxen sodium 550 mg/day 
and recommendations for the wound site care. The patients’ 
ages, period of hospitalization, comorbidities, laboratory 
parameters, perioperative bleeding amount, blood transfu-
sion, if any, and smoking habits were recorded. All patients 
were invited for SSI check with the intervals of 10 days until 
postoperative day 30. SSI was diagnosed according to the 
following criteria: purulent discharge (regardless of whether 
there is positive culture), positive culture of wound or wound 
discharge, presence of at least one of the following signs: 
pain, swelling, redness, warmth and wound-opening and 
surgeon’s opinion towards the infection [16]. Wound swabs 
were taken when clinically indicated. The patients who met 
one of the diagnosis criteria for surgical site infection within 
this period were recorded.
The conformity of numerical data with the normal dis-
tribution was tested with Shapiro-Wilk test. ANOVA and LSD 
tests were used for comparing the variables with normal 
distribution in 3 groups. The relationship between the cat-
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egorical variables was tested with the chi-squared test. SPSS 
22.0 software pack was used in the analyses. P < 0.05 was 
considered significant.
Sample size estimation
Sample size estimation was performed based on previ-
ous study results [14]. To find significant difference between 
rifampicin and povidone-iodine with effect size of 27% 
(%5 vs %32) minimum required sample size for each group 
was calculated as 90 (α = 0.05, 1-β = 0.90). G power package 
version 3.1.9.2 was used to perform sample size estimation.
RESULTS
The gynecologic cases and their rates were as follows, 
respectively: 135 patients had endometrial cancer (45%), 
94 patients had ovarian cancer (31.3 %), and 71 patients 
had cervical cancer (23.7%). The main characteristics of the 
patients are shown in Table 1.
The total number of incisional SSIs in the patients was 
28 (9.3%) (Group 1: 12, Group 2: 6, Group 3: 10). It was ob-
served that there was a statistically significant increase in 
the rate of incisional SSI as the period of hospitalization 
(p = 0.044), patient’s age (p = 0.003), existence of comor-
bidities (p = 0.001), and perioperative blood transfusion 
(p = 0.021) increased. The risk factors that can play a role in 
the occurrence of SSI are shown in Table 2.
No significant relationship was observed between the 
SSI and the subcutaneous agents used (p = 0.332) (Fig. 1).
DISCUSSION
The surgical site infection is one of the most important 
problems of gynecological surgery. Most of the studies pre-
viously conducted in the field of gynecology and obstetrics 
are on SSI after cesarean section [17 ,18] and less benign 
gynecological cases [19, 20]. There is a limited number of 
studies on the surgical site infections that occur after gy-
necologic oncology cases [21].
The factors they play role in the SSI formation can be 
classified into 3 groups: microbe-related risk factors, with 
Staphylococcus aureus and Streptococcus pyogenes; 
host-related risk factors, with morbid obesity, an index of dis-
ease severity, old age, protein-calorie malnutrition, steroid 
use, diabetes, immunodeficiency, cancer, and systemic infec-
tion; and operation-related risk factors, including prolonged 
hospital stay before surgery, duration of the operation, tis-
sue trauma, poor hemostasis, and foreign material in the 
wound. The performance of an intraabdominal procedure, 
operation time > 4 hours, a contaminated or dirty-infected 
operation, and concomitant illness of significance were 
other important factors [22]. Although it is not possible to 
fix the factors related to the patient, most of the risk fac-
tors related to surgical practice and microbe can be fixed. 
Therefore, taking measures for all risk factors that result in 
SSI will decrease the incidence of these infections.
One of the most important methods in reducing the SSIs is 
the monitoring and evaluation performed by the hospital in-
fection control committees as also applied in our hospital [23]. 
For this purpose, the rates of SSIs in the hospitals and the 
active pathogens must be specified, and the appropriate 
antibiogram charts must be formed for these. The results 
obtained from these evaluations must be shared with the 
surgery team, and studies must be conducted for continu-
ous quality improvement for decreasing the infections. Be-
sides appropriate surgical antibiotic prophylaxis is crucial.
Table 1. The baseline characteristics of the patients
Variables Saline (n = 100) Saline + Rifampicin (n = 100) Saline + 10% povidone-iodine (n = 100) p value
Age† [yr] 59.31 ± 8.81A 55.38 ± 11.18B 59.47 ± 10.48A 0.021*
Hospitalization† [day] 4.09 ± 0.96 4.4 ± 1.26 4.25 ± 1.04 0.353
SC thickness† [cm] 4.9 ± 1.4 4.98 ± 1.87 4.72 ± 1.25 0.789
PO blood loss† [mL] 208.1 ± 147.75B 372.3 ± 275.97A 218.1 ± 197.31B 0.001*
BMI† 22.2 ± 2.72 23.16 ± 3.47A 21.74 ± 2.39B 0.013*
Hemoglobin† [g/dL] 10.78 ± 1.08 10.86 ± 1.21 10.81 ± 1.29 0.961
Comorbid disease‡  14 (14) 14 (14.1) 16 (16) 0.906
SC drain‡ 12 (12)B 33 (33)A 18 (18)B 0.001*
SC suture‡ 67 (67) 64 (64) 57 (57) 0.324
İncision‡ Pfannenstiel 
Midline 
2 (2) 2 (2) 1 (1) 0.816
98 (98) 98 (98) 99 (99)
Smoking‡ 26 (26) 30 (30) 22 (22) 0.445
Blood transfusion‡ 10 (10) 15 (15) 10 (10) 0.435
†mean ± st.deviation; ‡Count(percent); *Significant at 0.05 level (A is significantly higher than B); SC — Subcutaneous; PO — Peroperative; BMI — Body Mass Index;  
CRP — C reactive protein
516
Ginekologia Polska 2020, vol. 91, no. 9
www. journals.viamedica.pl/ginekologia_polska
Wound site irrigation with serum saline solution, pov-
idone-iodine, or antibiotics was mentioned among the in-
traoperative and postoperative recommendations provided 
by the World Health Organization (WHO) for prevention 
of the surgical site infection, and it was stated that there 
was not sufficient evidence demonstrating that irrigation 
with serum saline solution reduced the risk of infection 
and that irrigation with povidone-iodine could be helpful 
in clean and clean contaminated wounds [10].
Subcutaneous antibiotics are more advantageous in 
terms of side effects, toxicity and efficacy than systemic anti-
biotics. The agents that could not be used systemically may 
also be used subcutaneously. There are also disadvantages 
such as tenderness and contact dermatitis [24].
Subcutaneous antibiotics can be used in different forms 
like solutions, gels, powders, creams, beads or implants. The 
frequently used antibiotics are cephalosporins, aminogly-
cosides, glycopeptides, chloramphenicol, rifampicin and 
bacitracin [25]. It is not easy to determine using which agent, 
how much, how long and in what form, for prophylaxis in dif-
ferent types of surgical wounds. For this reason, the efficacy 
and limits of topical antibiotic use at the surgical site have 
not been clear enough yet [26]. Besides the topical antibi-
otics, the efficacy of local anesthetics and local antiseptics 
have been observed in different studies [27]. 
It was observed that the use of prophylactic subcuta-
neous drain did not decrease the rates of subcutaneous 
hematoma, seroma, and infection even in obese patients 
[28, 29]. We also did not reveal a positive effect of subcuta-
neous hemovac drains on the incidence of SSI. At the same 
time the subcutaneous drains can cause discomfort and 
excess cost. These results are comparable to studies focusing 
on other indications like cesarean section [30]. Otherwise, 
studies demonstrating the benefit of subcutaneous drain-
age are also available [31]. Therefore, a definite conclusion 
cannot be obtained about the general use of prophylactic 
subcutaneous drainage in the surgery.
According to the result of a Cochrane review performed 
in 2014 about subcutaneous suture, it was stated that sub-
cutaneous tissue closure did not have any effect on the 
site infection in gynecologic abdominal surgery [32]. We 
Table 2. The risk factors that may play a role in SSI formation
Variables SSI (n = 28) No SSI (n = 272) p value
Age† [yr] 58.86 ± 9.27 57.97 ± 10.46 0.003*
Hospitalization† [day] 4.57 ± 0.96 4.21 ± 1.11 0.044*
Sc thickness† [cm] 4.96 ± 1.97 4.86 ± 1.48 0.977
PO blood loss† [mL] 383.93 ± 312.12 254.04 ± 212.1 0.235
BMI† 23.14 ± 3.57 22.29 ± 2.87 0.876
Hemoglobin† [g/dL] 10.89 ± 1.2 10.81 ± 1.19 0.668
Comorbid disease‡ 15 (55.6) 29 (10.7) 0.001*
SC drain‡ 9 (32.1) 54 (19.9) 0.128







Smoking‡ 9 (32.13) 69 (25.4) 0.436












†mean ± st.deviation; ‡Count (percent); *Significant at 0.05 level; SSI — Surgical Site Infection; SC — Subcutaneous; PO — Peroperative; BMI — Body Mass Index;  
CRP — C reactive protein
Figure 1. Relationship between subcutaneous agents and SSI
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also did not find any effect of the subcutaneous thickness 
and the presence of subcutaneous suture on the SSIs. Also, 
considering the potential negative effects like bacterial 
contamination or tissue reaction, the subcutaneous sutures 
should be questioned.
In our study, we observed that the rate of SSI increased 
as the patient’s age increased, and that this outcome was 
similar to the outcomes of many studies that were previ-
ously conducted [33]. This can be related to the decrease 
in the normal defense mechanisms and increase in the 
incidence of chronic diseases such as diabetes mellitus in 
particular with the age. We observed more surgical site 
infections in the patients with chronic diseases as well. 
It was an expected outcome to observe an increase in the 
rate of surgical wound infection as the post-operative pe-
riod of hospitalization prolonged, because an increase is 
observed in the microorganisms in the skin flora of the 
patients who are hospitalized for a long period of time, and 
this flora can contain the resistant microorganisms observed 
in the hospitals. Therefore, discharging the patients as early 
as possible during the post-operative period will decrease 
the probability of surgical site infection [34]. The increase 
in the rate of wound infection as the rate of perioperative 
blood transfusion increases are parallel with the outcome of 
many studies that were previously conducted on this sub-
ject, and perioperative blood transfusion must be avoided 
unless mandatory [35].
In this study we conducted for comparing the efficacy 
of surgical wound irrigation performed with saline, 10% 
povidone-iodine, or rifampicin, SSI was most commonly 
observed in the saline group and least commonly observed 
in the povidone-iodine group. Despite the numerical dif-
ference between the groups, no statistically significant 
difference was observed between the agents in terms 
of preventing the SSI. Perhaps the most striking aspect 
of this study is the emergence of different result from 
our previous study on benign gynecological cases [14]. 
Our previous study revealed that SSI decreased significantly 
with subcutaneous rifampicin and 10% povidone-iodine 
irrigation compared to saline alone in benign gynecologic 
cases This different result between these two studies may 
suggest that defense mechanisms and risk factors in oncol-
ogy patients have changed and weakened, also the average 
age, chronic disease and blood transfusion rates are higher 
than the previous study. In benign gynecological cases, 
patients receive 3 doses of one type parenteral antibiotics 
during their hospital stay, while in oncology cases we give 
uninterrupted two type parenteral antibiotics until they are 
discharged. However, oncological cases stay in the hospi-
tal longer than other cases, and wound care is performed 
twice a day during their stay. Such differences between 
benign cases and oncological cases can lead to different 
results between the two studies. In addition, although there 
was no statistical difference, the least infection was in the 
povidone-iodine group and the most infection was in the 
saline group. This may indicate the possibility of statistically 
significant difference when more patients are evaluated in 
larger studies.
The facts that could not be partially foreseen such as 
limited number of patients, the possibility of existence of 
people with active infection in the team, and not having 
information on the hygienic condition of the patients dur-
ing the perioperative period are included in the limitations 
of our study.
This clinic trial is a preliminary study to present the re-
sults of the wound irrigation technique with rifampicin or 
povidone-iodine that we have used in our practice for many 
years and it may contribute to reaching the sufficient level 
of evidence on surgical wound infections in gynecologic 
oncology cases, which are still missing in the literature, and 
that it may be a guide for the studies that will be conducted 
on this subject in future.
CONCLUSIONS
Superficial incisional SSI rate in gynecologic oncology 
patients significantly increases as the period of hospitaliza-
tion (p = 0.044), patient’s age (p = 0.003), existing comor-
bidities (p = 0.001) and perioperative blood transfusion 
(p = 0.021) increased. However, it does not change when 
using subcutaneous rifampicin or povidone-iodine. Al-
though there was no statistical difference, the least infection 
was in the povidone-iodine group and the most infection 
was in the saline group. This may indicate the possibility 
of statistically significant difference when more patients 
are evaluated in larger studies. We believe that broader 
prospective randomized controlled trials are required to 
make a definitive comment on this issue.
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